282 research outputs found

    Simultaneous solution of Kompaneets equation and Radiative Transfer equation in the photon energy range 1 - 125 KeV

    Full text link
    Radiative transfer equation in plane parallel geometry and Kompaneets equation is solved simultaneously to obtain theoretical spectrum of 1-125 KeV photon energy range. Diffuse radiation field is calculated using time-independent radiative transfer equation in plane parallel geometry, which is developed using discrete space theory (DST) of radiative transfer in a homogeneous medium for different optical depths. We assumed free-free emission and absorption and emission due to electron gas to be operating in the medium. The three terms n,n2n, n^2 and (nxk)\displaystyle \bigg({\frac {\partial n}{\partial x_k}}\bigg) where nn is photon phase density and xk=(hνkTe)\displaystyle x_k= \bigg({\frac {h \nu} {k T_e}} \bigg) , in Kompaneets equation and those due to free-free emission are utilized to calculate the change in the photon phase density in a hot electron gas. Two types of incident radiation are considered: (1) isotropic radiation with the modified black body radiation IMBI^{MB} [1] and (2) anisotropic radiation which is angle dependent. The emergent radiation at τ=0\tau=0 and reflected radiation τ=τmax\tau=\tau_{max} are calculated by using the diffuse radiation from the medium. The emergent and reflected radiation contain the free-free emission and emission from the hot electron gas. Kompaneets equation gives the changes in photon phase densities in different types of media. Although the initial spectrum is angle dependent, the Kompaneets equation gives a spectrum which is angle independent after several Compton scattering times.Comment: 31 pages, 8 figures, Accepte

    Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer

    Get PDF
    This phase 1/2 study evaluated the dose-limiting toxicity and maximum tolerated dose of MLN2704, a humanized monoclonal antibody MLN591 targeting prostate-specific membrane antigen, linked to the maytansinoid DM1 in patients with progressive metastatic castration-resistant prostate cancer
    corecore